<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249208</url>
  </required_header>
  <id_info>
    <org_study_id>SENTINAC-01</org_study_id>
    <nct_id>NCT02249208</nct_id>
  </id_info>
  <brief_title>Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide for Breast Cancer Patients After Neoadjuvant Treatment.</brief_title>
  <acronym>SENTINAC-01</acronym>
  <official_title>Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide vs. Standard Technique After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sysmex España S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the detection rate and the false negative rate of
      sentinel lymph node (SLN) by superparamagnetic iron oxide (SPIO) alone or in addition to
      radioisotope and compared to the standard method (blue and radioisotope) after neoadjuvant
      chemotherapy in patients with node-positive breast cancer converted to node negative after
      treatment by ultrasound. A randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Identification of Sentinel node:

        -  Arm 1 (Tc+blue dye): Identification of SLN using the standard technique of sub-areolar
           injection of technetium-99m (Tc-99m) and vital blue dye before surgery.

        -  Arm 2 (Tc+SPIO): Identification of SLN using standard isotope technique of sub-areolar
           injection of technetium-99m (Tc-99m) before surgery and the magnetic technique with the
           sub-areolar injection of SPIO (Sienna+®) before surgery and detection with the SentiMag®
           probe. (Study)

        -  Arm 3 (SPIO alone): Identification of SLN using the magnetic technique with the
           sub-areolar injection of SPIO (Sienna+®) before surgery and detection with the SentiMag®
           probe. (Study)

      Sentinel node's excision of radioactive and / or blue and / or magnetic (colored
      brown-brown), detection guided by hand probe gamma radiation, colorimetric and / or and
      SentiMag® paramagnetic probe.

      Lymph nodes that are radioactive, blue, magnetic or palpable are considered SLNs and are
      resected and submitted for pathological analysis. The protocol required that at least 2 SLNs
      to be resected.

      In all cases a completion axillary lymphadenectomy nodes dissection (ALND) will be performed
      after SLN biopsy. All SLNs will be excised and submitted before performing the ALND.

      Characterization of the nodal status of patients with the detection rate and the false
      negative rate of SLN for each arm.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>False Negative Rate</measure>
    <time_frame>3 months</time_frame>
    <description>The proportion of number of patients with a negative SLN biopsy with the number of patients with axillary lymph node metastases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection Rate</measure>
    <time_frame>3 months</time_frame>
    <description>The Proportion of patients that SLNs was identified compared to total ALND patients.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tc+blue dye</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tc+SPIO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPIO alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tc+blue dye</intervention_name>
    <description>Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery</description>
    <arm_group_label>Tc+blue dye</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tc+SPIO</intervention_name>
    <description>Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery</description>
    <arm_group_label>Tc+SPIO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPIO alone</intervention_name>
    <description>Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery</description>
    <arm_group_label>SPIO alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven primary invasive breast cancer with clinical stage T1 through
             T3, N1 through N2, M0 according to the American Joint Committee on Cancer (AJCC)
             Cancer Staging Manual, seventh edition

          -  Completed or were planning to undergo neoadjuvant chemotherapy

          -  Prechemotherapy axillary nodal disease confirmed by fine-needle aspiration or
             core-needle biopsy

          -  The axilla is clinically and radiologically (by ultrasound) negative (ycN0)
             postchemotherapy and before surgery

          -  Removal of at least two SLNs

          -  Signed informed consent from each patient before study entry

        Exclusion Criteria:

          -  T4 tumors, cN3 or cM1

          -  The axilla is clinically and radiologically (by ultrasound) positive (ycN1)
             postchemotherapy

          -  Intolerance or hypersensitivity to the compounds or iron dextran or superparamagnetic
             iron oxide or to vital blue dye or radioactive product.

          -  Chronic iron overload

          -  Pacemaker or other metallic implantable device in the chest wall

          -  Failure to submit to medical study for geographical, social or psychological

          -  Patient deprived of liberty or under guardianship

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel T Rubio, MD. PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Vall D Hebron. Universidad Autónoma de Barcelona.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel T Rubio, MD. PhD.</last_name>
    <email>irubio@vhio.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Vall D Hebron.</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabel T Rubio, MD. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Espinosa-Bravo, MD. PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Sentinel Lymph Node</keyword>
  <keyword>Neoadjuvant Chemotherapy</keyword>
  <keyword>Clinically Node-Positive with biopsy-proven cN1</keyword>
  <keyword>False-negative Rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

